Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $57.80 | Total: $289.00 |
| 1 | 10 | $48.96 | Total: $489.60 |
| 1 | 25 | $41.48 | Total: $1,037.00 |
| 1 | 50 | $35.36 | Total: $1,768.00 |
| 1 | 100 | $30.60 | Total: $3,060.00 |
Overview
JHU395 is an orally-bioavailable prodrug of a lipophilic glutamine antagonist (GA), 6-diazo-5-oxo-L-norleucine (DON). It demonstrates delivery of DON to malignant peripheral nerve sheath tumor (MPNST) both in vitro and in vivo, resulting in significant antitumor activity in MPNST. Additionally, JHU395 exhibits plasma stability.
Chemical Properties
| Molecular Formula | C22H29N3O7 |
| Molecular Weight | 447.48 |
| CAS Numbers | 2079938-92-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(OC(C(C)(C)C)=O)(OC(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)C1=CC=CC=C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Lemberg KM, et al. The novel glutamine antagonist prodrug JHU395 has antitumor activity in malignant peripheralnerve sheath tumor. Mol Cancer Ther. 2020;19[2] 397-408.